We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Boston Scientific said that the FDA approved new directions for its Taxus Express2
drug-coated coronary stent, allowing doctors to perform magnetic resonance imaging
(MRI) on a patient soon after receiving the device.
Ypsomed, in collaboration with Safety Syringes, has designed a reusable Autoinjector
specifically for use with Safety Syringes' UltraSafe Drug Delivery Systems.
Mentor, a supplier of medical products in the U.S. and internationally, announced
that the FDA has posted information related to Mentor's silicone gel breast
implant premarket approval (PMA) application on its web site.
Wilbur Leopold, president of MIR Preclinical Services
(MIR), a Michigan-based corporation, and Sarah Bacus, founder, CEO and CSO of
Targeted Molecular Diagnostics (TMD), an Illinois limited liability company,
today announced the companies have formed a strategic alliance to offer greater
services and cost savings to clients.
Agile Software, a provider of product lifecycle management solutions, announced
that Transoma Medical, a company specializing in the use of wireless implantable
sensors for monitoring vital signs in biomedical research animals, is using
Agile 9 to help manage their business processes and meet compliance regulations
as they develop their first medical device.
Toshiba America Medical Systems released exclusive software upgrades (v3.5.1)
for the Infinix-i series vascular and cardiac imaging system to improve the
Vitrea 2 workstation.
Fresenius Medical Care, a provider of kidney dialysis, got a subpoena from U.S.
authorities conducting a civil and criminal probe into its relationships with
doctors.
Vivascience, a subsidiary of Sartorius AG, introduced the Vivapure 8-to-96 well
cobalt-chelate kit, a complete system for simultaneous purification of multiple
HIS-tagged proteins by Immobilized Metal Affinity Chromatography (IMAC).
Tucson, Ariz.-based ImaRx Therapeutics announced the beginning of treatment
for the first patient in a new Phase II clinical trial for its stroke treatment.
Neoprobe, a diversified developer of innovative oncology diagnostic and treatment
products and cardiovascular surgical and diagnostic products, announced that
it has completed a license agreement for U.S. Patent Nos. 6,418,338 and 6,760,612
B2 issued July 9, 2002 and July 6, 2004, respectively.